Q-omics provides the consensus-scored SRSF5 profile across patient tissues and cancer cell-line models. SRSF5 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SRSF5 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, SRSF5 protein abundance shows 25,279 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, LUAD, and GBM as cancer lineages where SRSF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRSF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRSF5 survival associations across molecular data types. SRSF5 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRSF5 RNA expression–survival associations across cancer types. High SRSF5 expression shows unfavorable associations in UVM, COAD and ACC, but favorable associations in BRCA, MESO and BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SRSF5 RNA expression.
This table summarizes SRSF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SRSF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRSF5 shows lower tumor expression in LUAD, COAD, UCEC, BRCA, LUSC and BLCA. The LUAD box plot shows higher SRSF5 RNA expression in normal versus tumor tissue (log2 FC = −0.547, t-test p < 0.001).
This table shows molecular features associated with SRSF5 in patient tissues and cancer cell lines. In patient samples, SRSF5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRSF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
